Chiltern Opens New Office in Argentina
Chiltern International Limited (Chiltern), a global clinical contract research organization (CRO) announced that it has opened a new office in Argentina.
Oscar Podesta, Chiltern Executive Director, Latin America, leads this endeavor.“Our office, strategically located in suburban Pilar, is a natural next step to our development in Argentina. The office’s state-of-the-art facilities and technology are designed to support our growing client needs in Mexico, Chile, Peru and throughout all Latin America, complementing Chiltern’s Sao Paulo, Brazil office,” commented Oscar.
“Chiltern’s opening of the Buenos Aires office in 2010 continues our globalization effort following the opening of four new offices in 2009,” stated Glenn Kerkhof, Chiltern CEO. “Chiltern’s strong presence in Argentina, Brazil, Mexico and the entire Latin American region demonstrates our commitment to providing high quality services globally.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
